This optimized multi-unit floating domperidone microballoons delivery system is expected to provide clinicians with a new choice of an economical, safe and more bioavailable formulation in the management of upper gastrointestinal motility disorders. While the control of drug release profiles has been a major aim of pharmaceutical research and development, the control of GI transit profiles of domperidone might result in the availability of new products with new therapeutic possibilities and substantial benefits for patients. Soon, the so-called 'once-a-day' formulations may be replaced by novel gastroretentive products with release and absorption phases of approximately 24 hours.